NasdaqGM:LNTHMedical Equipment
Is New PYLARIFY TruVu Approval Amid Sales Pressure Altering The Investment Case For Lantheus (LNTH)?
Earlier this year, Lantheus Holdings secured FDA approval for its PYLARIFY TruVu imaging agent and is awaiting a separate FDA decision on its LNTH-2501 diagnostic kit, expected by late June.
At the same time, projections of a 6.3% sales decline and pressure on operating margins highlight how rising costs and softer demand may temper the impact of these new products.
We’ll now examine how the PYLARIFY TruVu approval, alongside projected sales headwinds, reshapes Lantheus Holdings’ existing...